BioAge Labs, Inc.

Bleichmar Fonti & Auld LLP investigates BioAge Labs, Inc. for potential securities law violations after discontinuing azelaprag's Phase 2 trial due to safety concerns, causing a 76% stock drop. Investors are encouraged to seek legal options.

Bleichmar Fonti & Auld LLP investigates BioAge Labs, Inc. for potential federal securities law violations. BioAge discontinued its azelaprag Phase 2 trial due to safety concerns, causing a 76% stock drop. Investors may have legal options with no upfront costs.

Bleichmar Fonti & Auld LLP investigates BioAge Labs, Inc. for securities law violations after discontinuing its azelaprag Phase 2 trial due to safety concerns, causing a 76% stock drop. Investors are encouraged to seek legal options.

BioAge Labs halted the STRIDES Phase 2 study of azelaprag due to liver transaminitis in some subjects, with no issues observed in the tirzepatide-only group. The trial aimed to evaluate azelaprag's efficacy in weight reduction and safety in combination with tirzepatide. BioAge plans to analyze STRIDES data and share updates on azelaprag in Q1 2025, while advancing other therapeutic candidates targeting aging biology.

AI-based Clinical Trials Solution Provider Market to reach USD 7.64 billion by 2032 with a CAGR of 22.0%, driven by AI's role in trial design, patient recruitment, data analysis, and regulation, aiming to enhance speed, reduce costs, and improve data reliability.

The AI in Clinical Trials Market, valued at USD 1.59 Billion in 2023, is projected to reach USD 6.55 Billion by 2030, growing at a CAGR of 22.4%. AI technologies are revolutionizing clinical trials by expediting patient recruitment, optimizing trial design, and enhancing data management. North America leads the market due to its robust healthcare infrastructure and significant R&D investments. Deep learning dominates the technology segment, aiding in complex data analysis for more efficient clinical trials.

The AI in Clinical Trials Market is rapidly growing, with a projected increase from USD 1.59 billion in 2023 to USD 6.55 billion by 2030, driven by AI's role in expediting drug development, especially in oncology. Deep learning leads in technology segments, enhancing trial efficiency and precision. North America dominates the market due to its advanced healthcare infrastructure and R&D investments.